LINCOLN, Neb., Aug. 30, 2016 /PRNewswire/ -- Building on its expertise in reagent and dye production, LI-COR is expanding its services to include synthesis and conjugation services for early-phase cGMP production.
"We offer a variety of custom services and can apply our unique expertise in dye and probe development for intra-operative surgery to help researchers," says Bambi Reynolds, Sr. Business Development Manager. "We have expanded our production facility to accommodate contract manufacturing for both pre-clinical and early phase clinical applications."
LI-COR offers development and manufacturing of dyes and small molecules including custom derivatives of fluorescent dyes and Active Pharmaceutical Ingredient (API) manufacturing at its Lincoln, Nebraska facility.
"Our clients in need of dye conjugated biomolecules are able to benefit from our extensive experience in biology and chemistry services that we have developed for our instrumentation platforms," says Reynolds.
With more than 20 years of bioconjugation experience, LI-COR is a pioneer in the use of near-infrared technology as a detection method. In the early '90's LI-COR introduced near-infrared (NIR) DNA sequencing technology that has led to other pre-clinical applications including protein and small animal imaging using NIR. This preclinical development has led to two near-infrared dyes being translated into the clinical trials using targeted NIR as a method for both detection and treatment of various types of cancer.
LI-COR Biosciences is a leading innovator in systems for plant research, gas analysis, drug discovery, protein research, and small animal imaging. From studies ranging from global climate change to cancer research, scientists rely on LI-COR products and services to address important biological and environmental challenges. More at www.licor.com
SOURCE LI-COR Biosciences